Cubist Meeting With FDA After Cidecin Fails To Meet Endpoint Jan. 18, 2002 By Karen Young No Comments Cubist Pharmaceuticals Inc. said its investigational antibiotic, Cidecin, failed to meet its primary endpoint in the first of two pivotal Phase III trials for community-acquired pneumonia.Read More
Zonagen Opts To Move Forward Rather Than Explore Alternatives Jan. 17, 2002 By Karen Young No Comments
La Jolla Raises $51.6M Privately To Fund Late-Stage Clinical Trials Jan. 17, 2002 By Karen Young No Comments
Zonagen Opts To Move Forward Rather Than Explore Alternatives Jan. 17, 2002 By Karen Young No Comments
La Jolla Raises $51.6M Privately To Fund Late-Stage Clinical Trials Jan. 17, 2002 By Karen Young No Comments
